• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    8/22/23 9:06:03 AM ET
    $ANEB
    $AXLA
    $CPHI
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ANEB alert in real time by email

    Gainers

    • Axcella Health (NASDAQ:AXLA) shares increased by 59.1% to $0.28 during Tuesday's pre-market session. The company's market cap stands at $20.5 million.
    • Fulcrum Therapeutics (NASDAQ:FULC) stock increased by 35.45% to $5.31. The company's market cap stands at $328.2 million.
    • G Medical Innovations (NASDAQ:GMVD) shares rose 32.12% to $0.21. The market value of their outstanding shares is at $2.0 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares rose 19.35% to $0.21. The market value of their outstanding shares is at $31.4 million.
    • Matinas BioPharma Hldgs (AMEX:MTNB) shares rose 15.79% to $0.19. The company's market cap stands at $41.2 million.
    • OpGen (NASDAQ:OPGN) shares rose 15.0% to $0.23. The company's market cap stands at $2.0 million.

    Losers

    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock fell 16.2% to $0.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.8 million.
    • Etao International Co (NASDAQ:ETAO) stock fell 14.25% to $0.36. The market value of their outstanding shares is at $36.8 million.
    • China Pharma Holding (AMEX:CPHI) shares decreased by 10.01% to $0.25. The company's market cap stands at $2.8 million.
    • Anebulo Pharmaceuticals (NASDAQ:ANEB) shares fell 9.39% to $2.8. The market value of their outstanding shares is at $71.7 million.
    • Journey Medical (NASDAQ:DERM) shares decreased by 9.14% to $1.79. The company's market cap stands at $32.4 million.
    • Kezar Life Sciences (NASDAQ:KZR) shares decreased by 8.6% to $1.17. The company's market cap stands at $85.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANEB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANEB
    $AXLA
    $CPHI
    $DERM

    CompanyDatePrice TargetRatingAnalyst
    Fulcrum Therapeutics Inc.
    $FULC
    1/12/2026$20.00Overweight
    Analyst
    Fulcrum Therapeutics Inc.
    $FULC
    11/24/2025Buy
    Truist
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025$7.00Buy → Hold
    Jefferies
    Kezar Life Sciences Inc.
    $KZR
    10/17/2025Outperform → Mkt Perform
    William Blair
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    Fulcrum Therapeutics Inc.
    $FULC
    7/29/2025$4.00 → $12.00Neutral → Buy
    H.C. Wainwright
    Fulcrum Therapeutics Inc.
    $FULC
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $ANEB
    $AXLA
    $CPHI
    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

    4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:15:06 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Musso Alan A

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:10:05 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Tourangeau Greg

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    2/4/26 4:10:03 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    $AXLA
    $CPHI
    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 34,000 options to pur

    3/6/26 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

    CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET. The webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics' webs

    3/3/26 8:30:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $ANEB
    $AXLA
    $CPHI
    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Fulcrum Therapeutics

    Truist initiated coverage of Fulcrum Therapeutics with a rating of Buy

    11/24/25 8:30:36 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kezar Life Sciences downgraded by Jefferies with a new price target

    Jefferies downgraded Kezar Life Sciences from Buy to Hold and set a new price target of $7.00

    10/17/25 8:25:43 AM ET
    $KZR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    $AXLA
    $CPHI
    $DERM
    SEC Filings

    View All

    China Pharma Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - CHINA PHARMA HOLDINGS, INC. (0001106644) (Filer)

    3/3/26 4:05:29 PM ET
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Anebulo Pharmaceuticals Inc.

    15-12G - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)

    3/2/26 4:30:24 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $ANEB
    $AXLA
    $CPHI
    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Director English Aron R. bought $10,000,000 worth of shares (10,101,010 units at $0.99) (SEC Form 4)

    4 - Anebulo Pharmaceuticals, Inc. (0001815974) (Issuer)

    12/26/24 4:15:08 PM ET
    $ANEB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    12/10/24 12:32:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $ANEB
    $AXLA
    $CPHI
    $DERM
    Leadership Updates

    Live Leadership Updates

    View All

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

    BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

    3/11/25 7:00:00 AM ET
    $GRCE
    $MTNB
    $ONVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ANEB
    $AXLA
    $CPHI
    $DERM
    Financials

    Live finance-specific insights

    View All

    Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote

    2/24/26 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for

    2/17/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar

    11/12/25 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    $AXLA
    $CPHI
    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 6:15:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care